Vikramsingh Gujar

Therapeutic interventions for speech pathologies have evolved over time with an increase in our understanding of the underlying neuroanatomical basis and the types of interventions available. The following exploratory research considers the perspective of experts and therapists in examining the multifactorial influences on speech pathologies and the therapeutic potential of music-based interventions. Our findings not only highlighted the role of linguistic, neuroanatomical, and psychosocial social factors in speech fluency and recovery; It also highlights the importance of how the therapy is provided, including the language used during treatment, the patient’s mother tongue, and bilingual abilities. Bilingualism was found to impact stuttering patterns, with some patients demonstrating greater fluency in a second language due to reduced emotional pressure or due to more exposure to different phonemes and phonetic structures. The distinction between neurogenic and developmental stuttering further emphasizes the need for tailored therapy, with neurogenic cases benefiting from neuroplasticity-driven interventions. Psychological and social factors, including anxiety and bullying, were frequently cited as exacerbating speech difficulties, reinforcing the value of cognitive-behavioral approaches. The efficacy of traditional clinical interventions was ameliorated by alternative therapeutic approaches that were more holistic in treating speech disorders. As such, music therapy emerged as a promising adjunct intervention, particularly for individuals with autism spectrum disorder (ASD) and neurogenic speech disorders. Techniques such as rhythmic queueing and melodic intonation therapy were reported to improve speech fluency by engaging multiple brain regions and enhancing speech-motor coordination. Our findings suggest that personalized, interdisciplinary approaches integrating language considerations, psychological support, and music therapy can optimize treatment outcomes. Future research should explore the long-term efficacy of these methods and the integration of digital tools such as artificial intelligence and virtual reality in speech therapy.

Speech disorders encompass a complex interplay of neuroanatomical, genetic, and environmental factors affecting individuals’ communication ability. This review synthesizes current insights into the neuroanatomy, genetic underpinnings, and environmental influences contributing to speech disorders. Neuroanatomical structures, such as Broca’s area, Wernicke’s area, the arcuate fasciculus, and basal ganglia, along with their connectivity, play critical roles in speech production, comprehension, and motor coordination. Advances in the understanding of intricate brain networks involved in language offer insights into typical speech development and the pathophysiology of speech disorders. Genetic studies have identified key genes involved in neural migration and synaptic connectivity, further elucidating the role of genetic mutations in speech disorders, such as stuttering and speech sound disorders. Beyond the biological mechanisms, this review explores the profound impact of psychological factors, including anxiety, depression, and neurodevelopmental conditions, on individuals with speech disorders. Psychosocial comorbidities often exacerbate speech disorders, complicating diagnosis and treatment and underscoring the need for a holistic approach to managing these conditions. Future directions point toward leveraging genetic testing, digital technologies, and personalized therapies, alongside addressing the psychosocial dimensions, to improve outcomes for individuals with speech disorders. This comprehensive overview aims to inform future research and therapeutic advancements, particularly in treating fluency disorders like stuttering.

Speech disorders encompass a complex interplay of neuroanatomical, genetic, and environmental factors affecting individuals' communication ability. This review synthesizes current insights into the neuroanatomy, genetic underpinnings, and environmental influences contributing to speech disorders. Neuroanatomical structures such as Broca's area, Wernicke's area, the arcuate fasciculus, and basal ganglia, along with their connectivity, play critical roles in speech production, comprehension, and motor coordination. Advances in functional neuroimaging have highlighted the intricate brain networks involved in language, offering insights into typical speech development and the pathophysiology of speech disorders. Genetic studies have identified key genes involved in neural migration and synaptic connectivity, further elucidating the role of genetic mutations in speech disorders, such as stuttering and speech sound disorders. Beyond the biological mechanisms, the review explores the profound impact of psychological factors, including anxiety, depression, and ADHD, on individuals with speech disorders. Psychosocial comorbidities often exacerbate speech disorders, complicating diagnosis and treatment and underscoring the need for a holistic approach to managing these conditions. Furthermore, the review emphasizes the importance of interdisciplinary interventions integrating speech therapy, cognitive-behavioral therapies, and neurogenetic insights to offer personalized treatment options. Future directions point toward leveraging genetic testing, digital technologies, and personalized therapies, alongside addressing the psychosocial dimensions, to improve outcomes for individuals with speech disorders. This comprehensive overview aims to inform future research and therapeutic advancements, particularly in treating fluency disorders like stuttering.

Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal condition affecting a significant portion of the global population. While GERD rarely leads to death, untreated cases can result in serious complications, including esophageal ulcers, bleeding, strictures, and Barrett’s esophagus, which increases the risk of esophageal cancer. Severe cases may require surgical intervention, costing between $8000 and $12,000. For patients with milder symptoms, proton pump inhibitors (PPIs) are often prescribed as a cost-effective treatment, averaging $163 per month, or $1500 to $2000 annually. However, PPIs are often misused, and their effectiveness is limited, reducing only about 65% of stomach acid. Misuse can lead to adverse effects, such as low stomach acid, indigestion, gas, diarrhea, constipation, and long-term risks like kidney disease, dementia, bone fractures, and cardiovascular disorders. Therefore, a more controlled approach to treatment is needed, utilizing drug delivery devices that minimize human error and comply with FDA and other regulatory standards to ensure patient safety. This paper explores recent advancements in GERD diagnosis and management, highlighting the potential of a patented device titled “A Swallowable Medical Device” that could revolutionize GERD treatment. This paper compares traditional diagnostic methods, such as endoscopy, pH monitoring, and esophageal manometry, with modern approaches like impedance-pH monitoring and high-resolution manometry. These advanced technologies allow healthcare providers to tailor treatment strategies to individual patient needs, enabling more accurate and comprehensive assessments. Additionally, a comparison with other patented devices is provided to facilitate understanding. The aim of this analysis is to offer insights into current practices, innovations, and the efficacy of the proposed “Swallowable Medical Device”. This information is made available globally to encourage further research and development in the field of GERD treatment.

Glutamate functions as the major excitatory neurotransmitter for primary sensory neurons and has a crucial role in sensitizing peripheral nociceptor terminals producing sensitization. Glutaminase (GLS) is the synthetic enzyme that converts glutamine to glutamate. GLS-immunoreactivity (-ir) and enzyme activity are elevated in dorsal root ganglion (DRG) neuronal cell bodies during chronic peripheral inflammation, but the mechanism for this GLS elevation is yet to be fully characterized. It has been well established that, after nerve growth factor (NGF) binds to its high-affinity receptor tropomyosin receptor kinase A (TrkA), a retrograde signaling endosome is formed. This endosome contains the late endosomal marker Rab7GTPase and is retrogradely transported via axons to the cell soma located in the DRG. This complex is responsible for regulating the transcription of several critical nociceptive genes. Here, we show that this retrograde NGF signaling mediates the expression of GLS in DRG neurons during the process of peripheral inflammation. We disrupted the normal NGF/TrkA signaling in adjuvant-induced arthritic (AIA) Sprague Dawley rats by the pharmacological inhibition of TrkA or blockade of Rab7GTPase, which significantly attenuated the expression of GLS in DRG cell bodies. The results indicate that NGF/TrkA signaling is crucial for the production of glutamate and has a vital role in the development of neurogenic inflammation. In addition, our pain behavioral data suggest that Rab7GTPase can be a potential target for attenuating peripheral inflammatory pain.

Glutamate functions as the major excitatory neurotransmitter for primary sensory neurons and has a crucial role in sensitizing peripheral nociceptor terminals producing sensitization. Glutaminase (GLS) is the synthetic enzyme that converts glutamine to glutamate. GLS-immunoreactivity (-ir) and enzyme activity are elevated in dorsal root ganglion (DRG) neuronal cell bodies during chronic peripheral inflammation, but the mechanism for this GLS elevation is yet to be fully characterized. It has been well established that, after nerve growth factor (NGF) binds to its high-affinity receptor tropomyosin receptor kinase A (TrkA), a retrograde signaling endosome is formed. This endosome contains the late endosomal marker Rab7GTPase and is retrogradely transported via axons to the cell soma located in DRG. This complex is responsible for regulating the transcription of several critical nociceptive genes. Here, we show that this retrograde NGF signaling mediates the expression of GLS in DRG neurons during the process of peripheral inflammation. We disrupted the normal NGF/TrkA signaling in adjuvant-induced arthritic (AIA) Sprague Dawley rats by pharmacological inhibition of TrkA or blockade of Rab7GTPase, which significantly attenuated the expression of GLS in DRG cell bodies. These results indicate that NGF/TrkA signaling is crucial for the production of glutamate and has a vital role in the development of neurogenic inflammation. In addition, our pain behavioural data suggest that Rab7GTPase can be a potential target for attenuating peripheral inflammatory pain.

Chronic inflammatory diseases are considered the most significant cause of death worldwide. Current treatments for inflammatory diseases are limited due to the lack of understanding of the biological factors involved in early-stage disease progression. Nerve growth factor (NGF) is a neurotrophic factor directly associated with inflammatory and autoimmune diseases like osteoarthritis, multiple sclerosis, and rheumatoid arthritis. It has been shown that NGF levels are significantly upregulated at the site of inflammation and play a crucial role in developing a robust inflammatory response. However, little is known about NGF’s temporal expression profile during the initial progressive phase of inflammation. This study aimed to determine the temporal expression patterns of NGF in rat skin (epidermis) during adjuvant-induced arthritis (AIA). Sprague Dawley rats were randomly divided into control and complete Freund’s adjuvant (CFA)-treated groups. Levels of NGF were evaluated following unilateral AIA at different time points, and it was found that peripheral inflammation due to AIA significantly upregulated the expression of NGF mRNA and protein in a biphasic pattern. These results suggest that NGF signaling is crucial for initiating and maintaining peripheral neurogenic inflammation in rats during AIA.

Chronic inflammatory diseases are considered the most significant cause of death worldwide. Current treatments for inflammatory diseases are limited due to the lack of understanding of the biological factors involved in early-stage disease progression. Nerve growth factor (NGF) is a neurotrophic factor directly associated with inflammatory and autoimmune diseases like osteoarthritis, multiple sclerosis, and rheumatoid arthritis. It has been shown that NGF levels are significantly upregulated at the site of inflammation and play a crucial role in developing a robust inflammatory response. However, little is known about NGF's temporal expression profile during the initial progressive phase of inflammation. This study aimed to determine the temporal expression pattern of NGF in rat skin during Adjuvant-Induced Arthritis (AIA). Sprague Dawley rats were randomly divided into control and Complete Freund's Adjuvant (CFA) treated groups. Levels of NGF were evaluated following unilateral AIA at different time points and it was found that peripheral inflammation due to AIA significantly upregulated the expression of NGF mRNA and Protein in a biphasic pattern. These results suggest that NGF signaling is crucial for initiating and maintaining peripheral neurogenic inflammation in rats during AIA.